Reviva shares surge 11.80% premarket as positive customer reviews highlight product efficacy and demand.
ByAinvest
Tuesday, Nov 18, 2025 5:15 am ET1min read
RVPH--
Reviva surged 11.80% in premarket trading following widespread positive customer reviews for its Reviva Glow product. The reviews highlighted the serum’s effectiveness in improving skin hydration, reducing bloating, and boosting energy, driven by ingredients like hyaluronic acid and adaptogenic herbs. Users praised its affordability, quick absorption, and benefits for digestive and metabolic health. The product’s 30-day money-back guarantee and positive testimonials, including reports of reduced bloating and enhanced energy, likely bolstered investor confidence in its market potential. The alignment of customer satisfaction with wellness trends and the product’s multifunctional benefits—ranging from skin health to metabolic support—appear to have driven the sharp premarket gain.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet